Q1 2024 · 13F-HR
Venrock Adviser, LLCholdings as filed
Filed 2024-05-15 · accession 0001104659-24-061948
$2.10B
Reported value
38
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $564.4M | 26.8% | 8,493,321 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $140.2M | 6.67% | 4,400,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $116.1M | 5.52% | 12,762,462 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $82.4M | 3.92% | 2,171,782 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $80.6M | 3.83% | 1,790,214 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $78.5M | 3.73% | 3,395,606 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $74.1M | 3.53% | 6,249,731 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $70.8M | 3.37% | 4,026,331 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $68.0M | 3.23% | 3,882,671 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $62.8M | 2.99% | 2,094,373 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $61.7M | 2.94% | 2,173,913 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $61.7M | 2.94% | 9,075,000 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $60.4M | 2.87% | 4,394,527 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $50.8M | 2.42% | 3,608,645 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $50.7M | 2.41% | 11,328,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $43.5M | 2.07% | 2,565,841 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $43.1M | 2.05% | 706,126 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $34.5M | 1.64% | 2,075,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $34.5M | 1.64% | 5,129,167 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $33.2M | 1.58% | 1,818,182 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $26.7M | 1.27% | 1,563,952 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $25.9M | 1.23% | 627,788 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $25.8M | 1.23% | 9,000,000 | Common | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $23.7M | 1.13% | 5,555,555 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $22.4M | 1.06% | 3,410,058 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $22.0M | 1.05% | 1,556,419 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $21.0M | 1.00% | 970,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $19.2M | 0.92% | 1,345,780 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $18.4M | 0.87% | 1,750,000 | Common | SOLE |
| 55234L105 | LYRAGBP | LYRA THERAPEUTICS INC | $16.0M | 0.76% | 2,576,093 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $15.4M | 0.73% | 350,000 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $14.2M | 0.68% | 3,405,133 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $11.8M | 0.56% | 3,422,675 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $8.1M | 0.39% | 1,555,556 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $7.2M | 0.34% | 555,554 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $6.3M | 0.30% | 937,113 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $5.2M | 0.25% | 250,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $872,115 | 0.04% | 77,042 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.